FDA finally approves Amylin's once-a-week diabetes injection

Share this article:

The third time was the charm for Amylin Pharmaceuticals' once-a-week diabetes injection drug. Bydureon was approved Friday, following two prior rejections. Amylin executives say the new drug's convenient regimen will give it a competitive advantage in the marketplace. Diabetes affects more than 25 million people in the U.S., including many nursing facility residents.


Share this article:

More in Products

FDA approves weight management drug

The U.S. Food and Drug Administration has approved Contrave as a treatment for chronic weight management. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation.

PDI introduces new swab

PDI introduces new swab

PDI has debuted the Prevantics® Device Swab, a chlorhexidine gluconate/alcohol solution that has received market authorization from the U.S. Food and Drug Administration for disinfecting needleless access sites prior to ...

Oregon Freeze Dry releases Easy Meal

Oregon Freeze Dry releases Easy Meal

A new brand from Oregon Freeze Dry is designed to help long-term care and other healthcare facilities prepare for a disaster.